The acquisition will complement Nestlé Health Science’s current weight management solutions.
PronoKal is a comprehensive, medically supervised weight loss system that is personalised to each customer. It includes a very-low-calorie ketogenic diet, physical exercise, support from nutrition and lifestyle coaches, and applied genomics. PronoKal is based in Spain and has a strong presence in Southern Europe.
“Figuring out a healthy way to lose weight and to stick to the program can be daunting. With medical supervision, healthy ketogenic meals and always-on support through the app, PronoKal is designed to take the confusion and stress out of weight loss, supporting people through their weight management journey,” said Greg Behar, CEO of Nestlé Health Science. “The acquisition of PronoKal adds a new dimension to our weight management portfolio and will enable us to help more people lead healthier lives.”
“Nestlé Health Science shares our commitment to healthy and effective weight management solutions,” said Andreu Puig, PronoKal Group’s CEO. “With PronoKal’s proven system and Nestlé Health Science’s reach and scientific expertise, we will continue our strong growth and bring PronoKal to more people around the world.”
Financial details of the transaction are not being disclosed. The deal is expected to close in Q1 2022.
Linklaters’ team was led by Corporate and M&A counsel José María López.
